Corporate Updates

Aquilonis partners with Clinical Solutions International, LLC


Aquilonis, a mobile software products and solutions company located in Bangalore, India and Boston, Massachusetts, USA has announced a strategic team alliance and partnership with Clinical Solutions International (CSI), LLC to make their mobile communications solutions available to the medical device community.

Aquilonis has teamed with CSI enabling them to now offer these services to the medical device and manufacturers and healthcare solutions companies. Working together, Aquilonis and CSI will offer customers a broader scope of high quality innovative solutions to today’s rapidly expanding global market of telemedicine. Their combined diverse experiences and strong penchant for innovation and quality will ensure that their customers receive only the highest quality service. With Aquilonis vast knowledge of custom mobile application development clients within the medical device manufacturing community will receive superior software development to meet their individual specific requirements. Aquilonis with their Custom Mobile Application Development Services will help medical device companies stay ahead of competitors, maintain superior mobility and eliminate obstacles in the path of the development process while saving both time and money.

Partnering with CSI will enable Aquilonis to expand their reach to more medical device and healthcare customers. Aquilonis has built a strong reputation developing complex mobile software solutions that are ideal for the telemedicine market. Their prime initial medical markets will be Home Health Care and the mobile applications of their customized software solutions for devices designed for pre-hospital emergency medicine. Working with Aquilonis will bring added value to customers looking for customized fully documented and tested mobile data transmission solutions.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News


Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe to our Newsletter
To Top